When is the right time to check the PSA box?
February 5, 2013 Testing for prostate cancer may not get any less confusing anytime soon. But researchers say the much-maligned PSA screening test is worthwhile if it's used for the right men at the right time.
Radiation therapist Jean Etienne holds a range compensator, which shapes the depth to which the proton beam enters a patient's body to target a tumor.
October 29, 2012 Proton therapy can be targeted much more precisely than regular radiation. The hope is that it translates into far fewer side effects, such as impotence and incontinence. But it also costs twice as much as regular radiation. And there's no proof it's more effective — it could potentially be worse, say some radiation experts.
<iframe src="http://www.npr.org/player/embed/163635298/163845729" width="100%" height="290" frameborder="0" scrolling="no">
Dr. Karen Lindsfor, a radiologist at the University of California, Davis, Medical Center, reads a mammogram in Sacramento, Calif.
September 6, 2012 There are conflicting guidelines on when women should get mammograms and mounting questions on when the PSA blood test for prostate cancer is worthwhile. We asked how people are sorting things out.
Surgery for prostate cancer shouldn't be an automatic choice, a new study says.
July 18, 2012 A study of more than 700 men with prostate cancer found no difference in rates of death among men who had their prostates surgically removed compared to those who didn't. The findings suggest that men with low-risk cancers could forgo surgery.
May 28, 2012 A federal task force's recommendations against routine blood tests for prostate cancer raises big questions about how to interpret medical evidence and what role expert panels should play in how doctors practice. But those questions aren't easy to answer.
<iframe src="http://www.npr.org/player/embed/153879847/153883324" width="100%" height="290" frameborder="0" scrolling="no">
May 24, 2012 Johns Hopkins researcher round that nearly three-quarters of primary care doctors they surveyed said their patients expected regular PSA screening to continue. The findings suggest there will be
May 23, 2012 The U.S. Preventive Services Task Force said the harms, such as false alarms and unnecessary surgeries that leave some men impotent and incontinent, outweigh the benefits of routine PSA blood testing for prostate cancer. But it's far from clear that doctors and their patients will heed the advice.
Terry Dyroff, at home in Silver Spring, Md., got a PSA blood test that led to a prostate biopsy. The biopsy found no cancer, but it gave him a life-threatening infection.
Jose Luis Magana/AP
May 21, 2012 The U.S. Preventive Services Task Force says the testing doesn't save enough lives to justify the risk of unnecessary surgery and radiation. But one testing supporter says, "If all PSA screening were to stop, there would be thousands of men who would unnecessarily suffer and die from prostate cancer."
<iframe src="http://www.npr.org/player/embed/153234671/153224081" width="100%" height="290" frameborder="0" scrolling="no">
April 18, 2012 Billionaire Warren Buffett was tested for prostate cancer at an age when most men are not. The evidence suggests that in most cases the harms of treatment of prostate cancer in elderly men outweigh its benefits.
The problem of breast cancer overdiagnosis with mammograms is similar to the dilemma faced by men diagnosed with prostate cancer because of a PSA test.
April 3, 2012 Norwegian scientists say as many as 1 in every 4 cases of breast cancer doesn't need to be found because it would never have caused symptoms or death. They also question a fundamental justification of mammography: that it finds more cancers when they're early and more curable.
March 12, 2012 Researchers found a 15 percent lower risk of prostate cancer among circumcised men than those who hadn't been circumcised. But the study doesn't prove that circumcision would work, though there're some reason to think it might.
December 7, 2011 An panel of experts convened by the National Institutes of Health suggests doctors should rethink their approach to treating prostate cancers. One of the recommendations is most low-risk prostate tumors shouldn't be labeled as cancer in the first place.
October 26, 2011 Confused about the fuss over PSA screening for prostate cancer? A commentary in the New England Journal of medicine says there's a middle ground between business-as-usual and throwing PSA tests out altogether.
Former House Speaker Newt Gingrich makes a point during the presidential debate sponsored at Dartmouth College in Hanover, New Hampshire, Tuesday night.
October 12, 2011 Newt Gingrich invoked Dr. Andrew von Eschenbach, former head of the National Cancer Institute, in criticizing proposed changes in prostate cancer screening. A close watcher of von Eschenbach at NCI questioned whether he is the right person to lean on.
October 12, 2011 In the first hour of Talk of the Nation, the political junkie, and screening and treating prostate cancer. In the second hour, the life of Mary Boleyn, and the art and science of creating a successful brand name.
NPR thanks our sponsors
Become an NPR sponsor